{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:17:27Z","timestamp":1790781447372,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.09.002","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:45:45Z","timestamp":1756914345000},"page":"e1134-e1144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment Accessibility, Availability, and Healthcare Costs for Multiple Myeloma in South Asian Countries"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-6585","authenticated-orcid":false,"given":"Uday","family":"Yanamandra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2308-7164","authenticated-orcid":false,"given":"Celine","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5411-4646","authenticated-orcid":false,"given":"Roopika","family":"Peela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu Jafar Mohammad","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-8704","authenticated-orcid":false,"given":"Thinley","family":"Dorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Juneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5286-7359","authenticated-orcid":false,"given":"Aye Aye","family":"Gyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ayaz","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buddhika","family":"Somawardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin Lutful","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishesh","family":"Poudyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Wimalachandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeba","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senani","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-8491","authenticated-orcid":false,"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2025.09.002_bib0001","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma","volume":"4","author":"Cowan","year":"2018","journal-title":"Jama Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.09.002_bib0002","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","article-title":"Clinical profiles of multiple myeloma in Asia: an Asian myeloma network study","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.09.002_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-438","article-title":"Diagnosed hematological malignancies in Bangladesh-a retrospective analysis of over 5000 cases from 10 specialized hospitals","volume":"14","author":"Hossain","year":"2014","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.09.002_bib0004","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12288-021-01485-y","article-title":"A multicenter study of clinical presentations and outcomes of multiple myeloma in Pakistan: the real-world analysis in a resource-constrained country","volume":"38","author":"Saeed","year":"2022","journal-title":"Ind J Hematol Blood Transf"},{"key":"10.1016\/j.clml.2025.09.002_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.heliyon.2024.e39698","article-title":"A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia","volume":"10","author":"Chng","year":"2024","journal-title":"Heliyon"},{"issue":"10","key":"10.1016\/j.clml.2025.09.002_bib0006","first-page":"642","article-title":"Unmet need and potential barriers for chimeric antigen receptor T cell therapy in India","volume":"29","author":"Singh","year":"2023","journal-title":"Transplantat Cell Ther, Offic Publ Am Soc Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.09.002_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12288-016-0773-9","article-title":"Consensus in the management of multiple myeloma in India at myeloma state of the art 2016 conference","volume":"33","author":"Yanamandra","year":"2017","journal-title":"Ind J Hematol Blood Transf"},{"issue":"4","key":"10.1016\/j.clml.2025.09.002_bib0008","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s12288-018-1026-x","article-title":"Myeloma at cross roads in India","volume":"34","author":"Yanamandra","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"10","key":"10.1016\/j.clml.2025.09.002_bib0009","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1080\/10428194.2018.1427858","article-title":"Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop","volume":"59","author":"Tan","year":"2018","journal-title":"Leukemia Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2025.09.002_bib0010","first-page":"54","article-title":"Transplant programs in APBMT: blood and marrow Transplant activity report from Myanmar: APBMT Meeting 2018, Taiwan","volume":"2","author":"Gyi","year":"2019","journal-title":"Blood Cell Ther"},{"issue":"1","key":"10.1016\/j.clml.2025.09.002_bib0011","article-title":"Haematopoietic stem cell transplant trends in Pakistan: activity survey from Pakistan bone marrow transplant group","volume":"2023","author":"Ali","year":"2023","journal-title":"J Transplant"},{"issue":"8","key":"10.1016\/j.clml.2025.09.002_bib0012","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.clml.2022.04.013","article-title":"Lack of renal recovery predicts poor survival in patients of multiple myeloma with renal impairment","volume":"22","author":"Sharma","year":"2022","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2025.09.002_bib0013","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.clml.2025.02.006","article-title":"Antibody response to pneumococcal, influenza, and COVID-19 vaccination in patients with multiple myeloma","volume":"25","author":"Singh","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.clml.2025.09.002_bib0014","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","article-title":"Clinical profiles of multiple myeloma in Asia: an Asian myeloma network study","volume":"89","author":"K\u0131m","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.09.002_bib0015","first-page":"87","article-title":"Trends in disease indications for hematopoietic stem cell transplantation in the Asia-Pacific region: a report of the Activity Survey 2017 from APBMT","volume":"5","author":"Iida","year":"2022","journal-title":"Blood Cell Ther"},{"issue":"1","key":"10.1016\/j.clml.2025.09.002_bib0016","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12955-024-02227-0","article-title":"Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database","volume":"22","author":"Dixit","year":"2024","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.clml.2025.09.002_bib0017","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00277-019-03602-4","article-title":"Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries","volume":"98","author":"Hungria","year":"2019","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.09.002_bib0018","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S2352-3026(25)00040-7","article-title":"CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India","volume":"12","author":"Paruzzo","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.09.002_bib0019","article-title":"Response and survival estimates of patients with plasma cell myeloma in a resource-constrained setting using protocols from high-income countries: a single-center experience from Sri Lanka","volume":"8","author":"Hewamana","year":"2022","journal-title":"JCO Global Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.09.002_bib0020","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.7314\/APJCP.2016.17.4.1833","article-title":"Multiple Myeloma: a retrospective analysis of 61 patients from a tertiary care center","volume":"17","author":"Sultan","year":"2016","journal-title":"Asian Pacific J Ca Prevent"},{"key":"10.1016\/j.clml.2025.09.002_bib0021","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/GO.20.00625","article-title":"Survival outcomes of newly diagnosed multiple myeloma at a tertiary care center in North India (IMAGe: 001A Study)","volume":"7","author":"Yanamandra","year":"2021","journal-title":"JCO Global Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.09.002_bib0022","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40258-024-00877-1","article-title":"Cost-effectiveness of novel agent regimens for transplant-eligible newly diagnosed multiple myeloma patients in India","volume":"22","author":"Dixit","year":"2024","journal-title":"Appl Health Eco Health Policy"},{"key":"10.1016\/j.clml.2025.09.002_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1065737","article-title":"Financial toxicity of cancer treatment in India: towards closing the cancer care gap","volume":"11","author":"Prinja","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.clml.2025.09.002_bib0024","doi-asserted-by":"crossref","first-page":"100514","DOI":"10.1016\/j.lansea.2024.100514","article-title":"Access to timely cancer treatment initiation in India: extent, determinants and trends","volume":"32","author":"Halder","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"1","key":"10.1016\/j.clml.2025.09.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2017.03.026","article-title":"Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries","volume":"19","author":"de Magalh\u00e3es Filho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"04","key":"10.1016\/j.clml.2025.09.002_bib0026","first-page":"518","article-title":"Understanding the constraints and optimization of serum immunofixation electrophoresis and serum free light chains for detecting monoclonal proteins: a single-center experience","volume":"15","author":"Shastri","year":"2023","journal-title":"J Laborat Phys"},{"issue":"4","key":"10.1016\/j.clml.2025.09.002_bib0027","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/10428194.2018.1508675","article-title":"Real world experience with \u201cgeneric\u201d pomalidomide in relapsed refractory multiple myeloma","volume":"60","author":"Jandial","year":"2019","journal-title":"Leukemia Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2025.09.002_bib0028","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12288-019-01111-y","article-title":"Stem cell transplantation in multiple myeloma: very much alive and kicking","volume":"35","author":"Yanamandra","year":"2019","journal-title":"Ind J Hematol Blood Transfusion"},{"issue":"6","key":"10.1016\/j.clml.2025.09.002_bib0029","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.mjafi.2023.09.002","article-title":"Hematopoietic cell transplantation landscape in India","volume":"79","author":"Nair","year":"2023","journal-title":"Med J Armed Forces India"},{"issue":"13","key":"10.1016\/j.clml.2025.09.002_bib0030","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1080\/10428194.2021.1953011","article-title":"Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting","volume":"62","author":"Asrar","year":"2021","journal-title":"Leukemia Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2025.09.002_bib0031","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.hemonc.2020.06.002","article-title":"Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma","volume":"14","author":"Lad","year":"2021","journal-title":"Hematol\/Oncol Stem Cell Ther"},{"issue":"5","key":"10.1016\/j.clml.2025.09.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14123","article-title":"Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients","volume":"25","author":"Jandial","year":"2023","journal-title":"Transplant Infect Dis"},{"issue":"11","key":"10.1016\/j.clml.2025.09.002_bib0033","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/oncolo\/oyac143","article-title":"Access to and affordability of world health organization essential medicines for cancer in sub-Saharan Africa: examples from Kenya, Rwanda, and Uganda","volume":"27","author":"Kizub","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clml.2025.09.002_bib0034","doi-asserted-by":"crossref","first-page":"67","DOI":"10.46989\/001c.92555","article-title":"Epidemiology, treatment trends, and outcomes of Multiple myeloma in the Middle East and Africa: a systematic review","volume":"6","author":"Mattar","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"1","key":"10.1016\/j.clml.2025.09.002_bib0035","first-page":"236","article-title":"Towards a unified approach for multiple myeloma care in Kenya-proceedings of the Inaugural Multiple Myeloma Congress","volume":"40","author":"Lotodo","year":"2021","journal-title":"Pan Afr Med J"},{"issue":"23","key":"10.1016\/j.clml.2025.09.002_bib39","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1001\/jama.2015.16843","article-title":"Payer and policy maker steps to support value-based pricing for drugs","volume":"314","author":"Bach","year":"2015","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.clml.2025.09.002_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075047","article-title":"Long-term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis","volume":"8","author":"Corso","year":"2013","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.clml.2025.09.002_bib0036","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s12913-024-10789-4","article-title":"Patterns and determinants of healthcare utilization and medication use before and during the COVID-19 crisis in Afghanistan, Bangladesh, and India","volume":"24","author":"Islam","year":"2024","journal-title":"BMC Health Serv Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:10:37Z","timestamp":1763773837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025028927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025028927"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Accessibility, Availability, and Healthcare Costs for Multiple Myeloma in South Asian Countries","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}